
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of September 2018

Commission File Number: 001-38547

Autolus Therapeutics plc
(Translation of registrant's name into English)

**Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, was incorporated in England and Wales on February 2, 2018.

In June 2018, the Company undertook a corporate reorganization pursuant to which (i) Autolus Therapeutics Limited became the direct holding company of Autolus Holdings (UK) Limited, a new holding company incorporated pursuant to the laws of England and Wales, (ii) Autolus Holdings (UK) Limited became the wholly owned subsidiary of Autolus Therapeutics Limited and the direct holding company of Autolus Limited, and (iii) Autolus Therapeutics Limited re-registered as a public limited company and change its name to Autolus Therapeutics plc.

Autolus Therapeutics plc is submitting this Report on Form 6-K to furnish its (i) unaudited balance sheet as of March 31, 2018 for Autolus Therapeutics plc, (ii) unaudited condensed balance sheets as of March 31, 2018 and September 30, 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc, and (iii) unaudited condensed statements of operations and comprehensive loss for the six months ended March 31, 2018 and 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc, which are furnished herewith as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, to this Report on Form 6-K. The furnished balance sheets and statements of operations and comprehensive loss as of and for the six-months ended March 31, 2018 do not reflect the corporate reorganization and initial public offering completed in June 2018.

EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
99.1	<u>Unaudited Balance Sheet as of March 31, 2018 for Autolus Therapeutics plc, formerly Autolus Therapeutics Limited</u>
99.2	<u>Unaudited Condensed Balance Sheets as of March 31, 2018 and September 30, 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc</u>
99.3	<u>Unaudited Condensed Statements of Operations and Comprehensive Loss for the Six Months Ended March 31, 2018 and 2017 for Autolus Limited, Predecessor to Autolus Therapeutics plc</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Autolus Therapeutics plc

Date: September 26, 2018

By: /s/ Andrew J. Oakley

Name Andrew J. Oakley

Title: Senior Vice President, Chief Financial Officer

AUTOLUS THERAPEUTICS PLC
(formerly AUTOLUS THERAPEUTICS LIMITED)
BALANCE SHEET
(UNAUDITED)
(Expressed in US Dollars, unless otherwise stated)

	March 31, 2018
TOTAL ASSETS	\$ —
Liabilities	—
Equity	—
Share capital (£0.00001 par value, one hundred thousand shares, issued and outstanding)	1
Additional paid in capital	—
Receivable from shareholder	(1)
Total equity	—
TOTAL LIABILITIES AND EQUITY	\$ —

AUTOLUS LIMITED
(PREDECESSOR to AUTOLUS THERAPEUTICS PLC)
CONDENSED BALANCE SHEETS
(UNAUDITED)

(In thousands, except share and per share amounts)

	March 31, 2018	September 30, 2017
Assets		
Current assets:		
Cash	\$120,674	\$ 137,070
Prepaid expenses and other current assets	11,198	5,412
Total current assets	131,872	142,482
Non-current assets:		
Property and equipment, net	11,590	6,180
Total assets	<u>\$143,462</u>	<u>\$ 148,662</u>
Liabilities and shareholders' equity		
Current liabilities:		
Accounts payable	\$ 3,613	\$ 1,946
Accrued expenses and other liabilities	11,888	3,087
Total current liabilities	15,501	5,033
Non-current liabilities:		
Long-term lease incentive obligation	258	265
Other long-term payables	604	763
Total liabilities	16,363	6,061
Shareholders' equity:		
Preferred shares, £0.00001 par value; 78,143,548 shares authorized, 78,002,897 and 78,143,548 shares issued and outstanding as of September 30, 2017 and March 31, 2018, respectively	1	1
Ordinary shares, £0.00001 par value; 119,203,434 shares authorized, 17,428,434 and 17,414,585 shares issued and outstanding at September 30, 2017 and March 31, 2018, respectively		—
Additional paid-in capital	196,981	194,351
Accumulated other comprehensive loss	2,258	(3,849)
Accumulated deficit	(72,141)	(47,902)
Total shareholders' equity	127,099	142,601
Total liabilities and shareholders' equity	<u>\$143,462</u>	<u>\$ 148,662</u>

AUTOLUS LIMITED
(PREDECESSOR to AUTOLUS THERAPEUTICS PLC)
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

	For the Six Months Ended March 31,	
	2018	2017
Grant income	\$ 657	\$ 881
Operating expenses:		
Research and development	17,191	7,012
General and administrative	7,413	3,327
Total operating expenses, net	23,947	9,458
Other income (expense):		
Interest income	470	54
Other expense	(3,625)	(15)
Total other income (expense), net	(3,155)	39
Net loss before income tax	(27,102)	(9,419)
Income tax benefit	2,863	1,827
Net loss attributable to ordinary shareholders	(24,239)	(7,592)
Other comprehensive (loss) income:		
Foreign exchange translation adjustment	6,108	(848)
Total comprehensive loss	(18,131)	(8,440)
Basic and diluted net loss per ordinary share	\$ (2.03)	\$ (0.80)
Weighted-average basic and diluted ordinary shares	13,339,613	11,731,496